Ex-Editas CEO Katrine Bosley chairs Arrakis board; Cardurion touts Polaris investment
→ After a surprise exit from Editas Medicine in January — which left many in shock and the stock plunging 21% $EDIT — ex-CEO Katrine Bosley will be heading the board of directors at Michael Gilman-led Arrakis Therapeutics as chairman. She is also a board member of Galapagos and Genocea Biosciences.
→ Cardurion Pharmaceuticals — focused on the treatment of heart failure and other cardiovascular diseases — has completed a private investment from Polaris Partners. Polaris joined existing investor Takeda in backing the startup and is sending its managing partner Amy Schulman to the board.
→ After snagging $56 million in fresh funding last month, AI upstart Healx is committing $20 million to invest in AI and drug discovery resources — up to $1 million per disease project in its Rare Treatment Accelerator (RTA) program. In addition, the company has welcomed Bruce Bloom to the role of chief collaboration officer. Bloom was the former president and CSO at Goldman Philanthropic Partnerships and is a founder and eventual CEO of non-profit Cures Within Reach.
→ Israeli-based Entera Bio — which released positive Phase II data for its oral parathyroid hormone drug Oral hPTH(1-34) in patients with hypoparathyroidism in September — has established a US headquarters in the Boston area. In addition, the company has brought on Jonathan Lieber as its US-based CFO. Lieber, a managing director at Danforth Advisors, recently served in the same role at Histogenics. He is credited for raising more than $300 million of equity and debt over his career, including a $110 million IPO at Altus Pharmaceuticals.